52 Antibody

Molecular Structure and Functional Role of Ro52/TRIM21

Ro52 (TRIM21) belongs to the tripartite motif (TRIM) protein family and contains:

• RING domain: Facilitates E3 ligase activity for ubiquitination.

• B-box domain: Mediates protein-protein interactions.

• Coiled-coil domain: Enables oligomerization.

• PRYSPRY (B30.2) domain: Binds immunoglobulin G (IgG) and pathogens .

Ro52 regulates interferon (IFN) signaling by ubiquitinating transcription factors like IRF3, IRF5, and IRF8, thereby modulating cytokine production . During viral infections, it targets antibody-coated pathogens for proteasomal degradation via the ADIN (antibody-dependent intracellular neutralization) pathway .

Anti-Ro52 in Autoimmune Diseases: Clinical Associations

Anti-Ro52 antibodies are prevalent in:

• Sjögren’s syndrome (SS): 83.5% of patients .

• Systemic lupus erythematosus (SLE) .

• Systemic sclerosis (SSc): Linked to pulmonary involvement .

• Idiopathic inflammatory myopathies (IIM): Associated with interstitial lung disease (ILD) .

Table 1: Prevalence of Anti-Ro52 Across Diseases

Isolated Anti-Ro52 as a Marker of Severe Disease

In Sjögren’s syndrome, isolated anti-Ro52 (without anti-Ro60/La) identifies a severe subset:

• Higher disease activity: ESSDAI scores increased by 2.4-fold .

• Vasculitis and cryoglobulinaemia: 67% vs. 28% in non-isolated cases .

• Delayed diagnosis: Symptoms manifest later (mean age: 62.2 years) .

Table 2: Clinical Features of Isolated vs. Combined Anti-Ro52 in SS

Data sourced from

Diagnostic and Prognostic Utility

• Diagnostic stratification: Isolated anti-Ro52 correlates with distinct clinical phenotypes. For example, in systemic sclerosis, it predicts ILD (OR=1.71) .

• Assay considerations: Anti-Ro52 detection requires separate testing from anti-Ro60 due to differing epitopes (linear vs. conformational) .

• Prognostic value: In scleroderma, isolated anti-Ro52 increases mortality risk (HR=2.1) .

Research Gaps and Future Directions

• Mechanisms of autoantigenicity: Why Ro52 becomes a target in autoimmunity remains unclear .

• Therapeutic implications: Targeting Ro52’s E3 ligase activity or IFN pathways could modulate disease .

• Longitudinal studies: Needed to assess anti-Ro52’s role in disease progression .